Skip to content
Home
About Us
Contributors
Publications
Aron 1 – Renal Cell Carcinoma
Aron 2 – Urothelial carcinoma
Aron 3 – Prostate Cancer
Contact Us
Menu
Home
About Us
Contributors
Publications
Aron 1 – Renal Cell Carcinoma
Aron 2 – Urothelial carcinoma
Aron 3 – Prostate Cancer
Contact Us
Publications
All our publications
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
Fiala O, et al.
Cancer Immunol Immunother.
2023
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study
Santoni M, et al.
Clin Exp Med.
2023
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project
Rizzo A, et al.
Clin Exp Metastasis.
2024
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project
Rizzo A, et al.
Target Oncol.
2024
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study.
Rizzo M, et al.
Sci Rep.
2024
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study
Fiala O, et al.
Target Oncol.
2024
Previous
Page
1
Page
2
Page
3
Next
